We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) recently introduced the D6 PHASER X-Ray Diffraction (“XRD”) system. The new benchtop XRD platform is designed with the analytical flexibility typically available only in larger, floor-standing systems.
The newest offering is built on the success of the Bruker D2 PHASER XRD system. The D6 PHASER benchtop XRD platform will support material analysis and advanced material discoveries by offering unmatched benchtop capabilities, versatility and a great user experience.
News in Detail
In contrast to conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. It combines the functionality of the floor-standing D8 platform with an innovative benchtop design that includes high X-ray excitation power and a versatile set of X-ray optics. The Motorized Air Scatter Screen enables dynamic beam optimization for optimum performance over the goniometer range.
Image Source: Zacks Investment Research
The D6 PHASER can be equipped with a range of sample stages for a large variety of X-ray diffraction applications, including capillary transmission, grazing incidence diffraction, X-ray reflectometry, residual stress, texture analysis and non-ambient investigations. The DaVinci stage interface allows swapping sample stages without realignment.
Combined with the DIFFRAC.SUITE software, the D6 PHASER provides flexibility for automated push-button methods or to customize measurement configurations for optimized data quality. The system does not require any external water cooling and has no special electrical requirements for convenience to bring versatile, high-performance XRD to any laboratory.
The D6 PHASER is available as a GxP-compliant solution and complies with the latest radiation protection and machinery directives. With its wide range of capabilities, the platform will enable more XRD applications for new markets and user communities.
Industry Prospects
Per a Research report, the global XRD market was valued at $690.1 million in 2019 and is expected to witness a CAGR of 3.2% by 2026.
Recent Highlights
At the 71st ASMS meeting held from Jun 4-8, 2023, BRKR announced transformative sensitivity on the 4D-Proteomics timsTOF platform with the launch of the timsTOF Ultra mass spectrometer. The company also introduced the VistaScan software for enhanced dia-PASEF 4D-Proteomics, the EVOQ DART-TQ+ mass spectrometer, the Impact II VIP ESI-TOF (time of flight) system and the TargetScreener 4D software for applied markets.
Earlier in May, Bruker completed the acquisition of ZONTAL Inc. The buyout strengthens Bruker BioSpin’s Integrated Data Solutions software division, which includes Mestrelab Research, Arxspan and Optimal.
Price Performance
In the past six months, Bruker has outperformed the industry. Shares of the company have rallied 10.1% against the industry’s fall of 11.7%.
Penumbra’s stock has surged 154.6% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 32.4% in the past year against the industry’s 22.6% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Rockwell Medical’s loss per share have narrowed from 58 cents to 48 cents for 2023 in the past 30 days. Shares of the company have surged 211.8% in the past year against the industry’s 22.5% decline.
RMTI’s earnings beat estimates in three of the trailing four quarters, the average surprise being 30.4%. In the last reported quarter, Rockwell Medical delivered an earnings surprise of 44.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
Bruker Corporation (BRKR - Free Report) recently introduced the D6 PHASER X-Ray Diffraction (“XRD”) system. The new benchtop XRD platform is designed with the analytical flexibility typically available only in larger, floor-standing systems.
The newest offering is built on the success of the Bruker D2 PHASER XRD system. The D6 PHASER benchtop XRD platform will support material analysis and advanced material discoveries by offering unmatched benchtop capabilities, versatility and a great user experience.
News in Detail
In contrast to conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. It combines the functionality of the floor-standing D8 platform with an innovative benchtop design that includes high X-ray excitation power and a versatile set of X-ray optics. The Motorized Air Scatter Screen enables dynamic beam optimization for optimum performance over the goniometer range.
Image Source: Zacks Investment Research
The D6 PHASER can be equipped with a range of sample stages for a large variety of X-ray diffraction applications, including capillary transmission, grazing incidence diffraction, X-ray reflectometry, residual stress, texture analysis and non-ambient investigations. The DaVinci stage interface allows swapping sample stages without realignment.
Combined with the DIFFRAC.SUITE software, the D6 PHASER provides flexibility for automated push-button methods or to customize measurement configurations for optimized data quality. The system does not require any external water cooling and has no special electrical requirements for convenience to bring versatile, high-performance XRD to any laboratory.
The D6 PHASER is available as a GxP-compliant solution and complies with the latest radiation protection and machinery directives. With its wide range of capabilities, the platform will enable more XRD applications for new markets and user communities.
Industry Prospects
Per a Research report, the global XRD market was valued at $690.1 million in 2019 and is expected to witness a CAGR of 3.2% by 2026.
Recent Highlights
At the 71st ASMS meeting held from Jun 4-8, 2023, BRKR announced transformative sensitivity on the 4D-Proteomics timsTOF platform with the launch of the timsTOF Ultra mass spectrometer. The company also introduced the VistaScan software for enhanced dia-PASEF 4D-Proteomics, the EVOQ DART-TQ+ mass spectrometer, the Impact II VIP ESI-TOF (time of flight) system and the TargetScreener 4D software for applied markets.
Earlier in May, Bruker completed the acquisition of ZONTAL Inc. The buyout strengthens Bruker BioSpin’s Integrated Data Solutions software division, which includes Mestrelab Research, Arxspan and Optimal.
Price Performance
In the past six months, Bruker has outperformed the industry. Shares of the company have rallied 10.1% against the industry’s fall of 11.7%.
Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus (LNTH - Free Report) and Rockwell Medical (RMTI - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Rockwell Medical carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has surged 154.6% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 32.4% in the past year against the industry’s 22.6% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Rockwell Medical’s loss per share have narrowed from 58 cents to 48 cents for 2023 in the past 30 days. Shares of the company have surged 211.8% in the past year against the industry’s 22.5% decline.
RMTI’s earnings beat estimates in three of the trailing four quarters, the average surprise being 30.4%. In the last reported quarter, Rockwell Medical delivered an earnings surprise of 44.4%.